Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion–Positive Pancreatic Adenocarcinoma: A Case Report.
- Resource Type
- Article
- Authors
- Reutter, Theresa; Fassunke, Jana; Püsken, Michael; Weber, Jan-Phillip; Binot, Elke; Eisert, Anna; Fischer, Rieke; Nogova, Lucia; Riedel, Richard; Schaufler, Diana; Scharpenseel, Heather; Scheffler, Matthias; Schulz, Holger; Waldschmidt, Dirk‐Thomas; Zander, Thomas; Merkelbach-Bruse, Sabine; Schirmacher, Peter; Büttner, Reinhard; Wolf, Jürgen; Michels, Sebastian
- Source
- JCO Precision Oncology. 4/20/2023, Vol. 7, p1-5. 5p.
- Subject
- *PROTEIN-tyrosine kinase inhibitors
*ADENOCARCINOMA
*CIRCULATING tumor DNA
- Language
- ISSN
- 2473-4284
Sequential tyrosine kinase inhibitor treatment and ctDNA monitoring is feasible in ROS1-positive PDAC—a histology agnostic paradigm. [ABSTRACT FROM AUTHOR]